Eli Lilly and Company ($LLY) Stock Forecast: Down 3.6% Today

What is Eli Lilly and Company?

A pharmaceutical company, Eli Lilly (NYSE: LLY), is recognized for its innovative drugs spanning various therapeutic areas, such as diabetes and weight-loss medications. The stock demonstrated notable bearish movement today.

Why is Eli Lilly and Company going down?

LLY stock is down 3.6% on Feb 3, 2026 16:56

• The promising Q4 revenue projections for Eli Lilly were overshadowed by the substantial investments in research and development. This financial strategy possibly instigated investor worries over the company's future profitability, contributing to the day's bearish market performance.
• Forecasts of positive stock momentum following the announcement of fresh data from Lilly's GLP-1 clinical trials failed to materialize as expected, potentially disappointing eager investors awaiting favorable outcomes.
• The noteworthy surge in institutional investors, with Peterson Wealth Services among them, signaled an optimistic long-term perspective on Eli Lilly. However, short-term profit-taking or apprehensions regarding R&D expenditures impacting immediate earnings might have influenced today's market downturn.

LLY Price Chart

LLY Technical Analysis

LLY News

Revvity, Inc. (NYSE:RVTY) Q4 2025 Earnings Call Transcript

Revvity, Inc. (NYSE: RVTY) reported strong Q4 2025 earnings, surpassing expectations with adjusted EPS of $1.70. The company achieved 4% organic growth, driven by robust performance in its diagnostics segment and gradual improvement in life sciences. Revvity issued a 2026 outlook with 2% to 3% organic growth, anticipating market recovery and highlighting significant share repurchase activity and the launch of its AI platform, Signals Synthetica.

https://www.insidermonkey.com/blog/revvity-inc-nyservty-q4-2025-earnings-call-transcript-1687929/

Eli Lilly Q4 Preview: Wall St Sees Revenue Beat On Weight-Loss Heft But R&D Costs Could Drag Profits

Eli Lilly is expected to report strong fourth-quarter revenue, primarily driven by its weight-loss and diabetes drugs like Mounjaro and Zepbound, with analysts projecting $17.90 billion, exceeding management's guidance. However, aggressive investments in research and development, which saw a 27% increase in the third quarter, could impact profitability. The company's future strategy also hinges on the potential launch of its oral GLP-1 drug, orforglipron, which analysts believe will be a significant growth driver.

https://finviz.com/news/297092/eli-lilly-q4-preview-wall-st-sees-revenue-beat-on-weight-loss-heft-but-rd-costs-could-drag-profits

Jim Cramer Says Eli Lilly "Could Announce Some New Data, and That Could Get the Stock Rolling"

Jim Cramer highlighted Eli Lilly (NYSE: LLY) as a stock to watch, noting that its earnings typically aren't the main driver, but rather new reports on GLP-1 clinical trials. He suggested that upcoming new data from Lilly could significantly boost the stock. Cramer also expressed bullish sentiment on the company's Mounjaro and its future pill form for GLP-1, predicting a massive increase in market capitalization.

https://finviz.com/news/297026/jim-cramer-says-eli-lilly-could-announce-some-new-data-and-that-could-get-the-stock-rolling

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Pfizer announced that its experimental obesity drug, PF’3944, achieved up to 12.3% weight loss in non-diabetic patients during a mid-stage trial. The drug, acquired through the Metsera deal, demonstrated continuous weight loss even after switching to monthly maintenance dosing. The company expects sustained results as the study progresses to week 64.

https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-experimental-drug-shows-up-123-weight-loss-mid-stage-trial-2026-02-03/

Peterson Wealth Services Raises Position in Eli Lilly and Company $LLY

Peterson Wealth Services significantly increased its stake in Eli Lilly and Company by 57.3% during the third quarter, making it their 18th largest portfolio position. Other institutional investors like Lazard Freres Gestion S.A.S. and Exencial Wealth Advisors LLC also boosted their holdings. Eli Lilly recently declared an increased quarterly dividend of $1.73, and analysts have set new, higher price targets for the company, maintaining a "Moderate Buy" consensus rating.

https://www.marketbeat.com/instant-alerts/filing-peterson-wealth-services-raises-position-in-eli-lilly-and-company-lly-2026-02-03/

Trending Today

Solana ($SOL) Crypto Forecast: Down 6.0% Today

Cosmos ($ATOM) Crypto Forecast: Up 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.9% Today

Gold ($XAU) Commodity Forecast: Up 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Revvity ($RVTY) Stock Forecast: Down 5.3% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.1% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.1% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Down 6.1% Today

FedEx Corporation ($FDX) Stock Forecast: Up 5.5% Today

Eli Lilly and Company Price History

03.01.2026 - LLY Stock was down 3.6%

• The promising Q4 revenue projections for Eli Lilly were overshadowed by the substantial investments in research and development. This financial strategy possibly instigated investor worries over the company's future profitability, contributing to the day's bearish market performance.
• Forecasts of positive stock momentum following the announcement of fresh data from Lilly's GLP-1 clinical trials failed to materialize as expected, potentially disappointing eager investors awaiting favorable outcomes.
• The noteworthy surge in institutional investors, with Peterson Wealth Services among them, signaled an optimistic long-term perspective on Eli Lilly. However, short-term profit-taking or apprehensions regarding R&D expenditures impacting immediate earnings might have influenced today's market downturn.

30.09.2025 - LLY Stock was up 2.0%

• Eli Lilly (LLY) surpassed Q3 earnings and revenue expectations, demonstrating robust financial performance.
• Collaboration with NVIDIA on a high-performance supercomputer underscores Lilly's dedication to technological advancements in pharmaceutical research.
• Aggressive acquisitions in the biotech and gene therapy sectors signal a strategic effort to diversify its pipeline and spur long-term growth.
• Positive views from Wall Street and Buy recommendations are boosting investor confidence and contributing to the upward trend of the stock.

05.00.2026 - LLY Stock was down 3.6%

• The stock's decline could potentially be linked to a lawsuit filed by the Indiana Attorney General accusing the company of being part of a scheme to increase insulin prices. This legal issue and the resulting negative attention likely shook investor confidence in the company's financial strength and standing.
• Although Eli Lilly was previously identified as a promising AI-powered medical stock for 2026, the unfavorable news related to the lawsuit overshadowed any positive perceptions of the company's technological progress.
• Additionally, the decision by Eli Lilly to lower prices in China, a move aimed at strengthening its position in a competitive market, might have raised worries about the company's profits and overall revenue outlook, influencing the downward trend in the market.
• The setbacks faced by competitors like Ultragenyx Pharmaceutical and Mereo BioPharma in their clinical trials, which led to notable drops in their stock prices, could have contributed to a broader pessimistic sentiment in the pharmaceutical industry, thereby impacting Eli Lilly's stock performance.

05.10.2025 - LLY Stock was up 5.0%

• Eli Lilly's $149 obesity drug deal with the White House has excited investors, fueling optimism for increased revenue and market share.
• The company's announcement of a substantial European manufacturing expansion for oral medicine has likely bolstered investor confidence in its growth potential.
• Surpassing expectations for third-quarter earnings and raising the annual forecast have contributed to the positive outlook on Eli Lilly, attracting more investors.
• The impressive performance of key drugs like Mounjaro and Zepbound, resulting in a notable revenue increase, has further reinforced Eli Lilly's growth prospects and driven up the stock price.

15.00.2026 - LLY Stock was down 5.0%

• The decline in Eli Lilly's stock may be linked to competitive anxieties triggered by Novo Nordisk's oral GLP-1 and the associated short-term risks.
• Despite positive financial results and strategic efforts, the increased ownership by Eastern Bank and Ashton Thomas Securities LLC could not fully counterbalance concerns over the competitive environment.
• Legal actions taken by Dover Corp. against leading insulin manufacturers, including Eli Lilly, on allegations of pricing manipulation leading to elevated drug costs, could have contributed to the negative outlook on Eli Lilly's stock.
• In summary, today's bearish trend on Eli Lilly's stock likely stems from a mixture of competitive fears, legal issues within the pharmaceutical sector, and potential risks impacting investor confidence in the company's future prospects.

28.00.2026 - LLY Stock was down 5.2%

• Profit-taking by investors post a period of strong performance could be a reason behind the bearish movement in LLY's stock.
• Market sentiment might have been influenced by broader economic factors or sector rotation, despite positive news regarding a strategic partnership for genetic biotech treatments targeting hearing loss.
• The FDA granting Breakthrough Therapy Designation to a competitor for treating cutaneous lupus erythematosus (CLE) might have diverted investor attention away from LLY, impacting its stock performance.
• Competition in the pharmaceutical industry, exemplified by positive Phase II results for an obesity candidate by a competitor, may have also played a role in the bearish movement in LLY's stock.

01.09.2025 - LLY Stock was up 11.2%

• Eli Lilly's stock (LLY) has seen a bullish trend, driven by encouraging recommendations from financial analysts on Wall Street, signaling a buy outlook among investors.
• Remarkably, Pfizer's agreement with the Trump administration concerning drug pricing has had a constructive impact on the pharmaceutical industry, including companies like Eli Lilly.
• Investor confidence, potentially from institutions or high-net-worth individuals, in Eli Lilly has intensified the upward trajectory of its stock.
• Additionally, Amgen's enhancement of its U.S. manufacturing footprint amid evolving tariff regulations could have indirectly contributed to the positive market sentiment around pharmaceutical firms like Eli Lilly.

01.09.2025 - LLY Stock was up 8.4%

• Eli Lilly's stock surged due to an announcement by President Donald Trump regarding a deal with Pfizer, which included the 'TrumpRx' platform aimed at reducing drug prices. This news boosted investor confidence in the pharmaceutical sector.
• The partnership between Pfizer and Washington had a significant impact on the industry, leading to companies like Eli Lilly benefiting from the positive market sentiment.
• Furthermore, bullish bets from high-net-worth investors, as reflected in publicly available options history, added to the upward momentum in Eli Lilly's stock.
• The overall optimism surrounding Eli Lilly, along with strategic expansions and favorable analyst recommendations, played key roles in the stock's impressive performance on the day.

07.00.2026 - LLY Stock was up 5.2%

• Eli Lilly's stock surged as reports surfaced about the company being in advanced talks to acquire Ventyx Biosciences, a move that could significantly expand its immunology portfolio.
• The prospective launches of cardiometabolic treatments by Eli Lilly, as projected by an industry analyst, have also contributed to investor optimism and confidence in the company's future revenue potential.
• The overall positive sentiment towards Eli Lilly's pipeline and potential acquisitions has likely fueled the bullish movement in the stock, showcasing investor enthusiasm for the company's growth prospects in the pharmaceutical market.

07.00.2026 - LLY Stock was up 5.4%

• Eli Lilly and Company (LLY) experienced a strong bullish movement following reports of advanced talks to acquire a biosciences company, showcasing market optimism for potential portfolio expansion and growth opportunities.
• The strategic initiatives by Eli Lilly and Company, including potential acquisitions and innovative treatments, have likely contributed to the positive market sentiment and bullish movement in the stock price.

11.11.2025 - LLY Stock was up 3.7%

• Eli Lilly's bullish movement can be attributed to the positive results from its obesity drug trial, showcasing the company's commitment to developing effective treatments.
• The removal of CVS from its employee drug plan following a drug snub highlights the competitive landscape in the pharmaceutical industry and Eli Lilly's strategic decisions to maintain market position.
• Market rumors of a potential takeover by Eli Lilly have also contributed to the stock's surge, indicating investor confidence in the company's growth strategy and potential acquisitions.
• Overall, Eli Lilly's strong performance reflects a combination of successful drug trials, strategic business decisions, and market speculations driving the stock's upward momentum.

06.00.2026 - LLY Stock was up 1.4%

• Eli Lilly's upward trend aligns with the positive outlook in the healthcare sector, fueled by advancements in medical technology and drug development.
• Recognition of Eli Lilly's integration of AI for growth and innovation could have heightened investor confidence, as pointed out by industry analysts.
• Optimistic results from Alumis Inc.'s Phase 3 trial for a psoriasis drug likely contributed to the positive sentiment towards pharmaceutical firms like Eli Lilly, resulting in increased buying interest.
• Indirectly, Pfizer's announcement of price hikes for branded medications may have indicated revenue growth opportunities in the pharmaceutical industry, potentially bolstering Eli Lilly's stock performance.